Heartflow released final results from its DECIDE Registry demonstrating how its AI-powered Plaque Analysis software significantly alters treatment plans for patients with suspected coronary artery disease (CAD).
Presented at SCCT 2025, data from nearly 1,000 patients across 15 U.S. sites show that more than half experienced changes in medical management when Heartflow’s technology was used, surpassing decisions made from coronary CT angiography (CCTA) alone. Patients guided by Plaque Analysis, including the new Plaque Staging tool, saw an average LDL cholesterol reduction of 18.7 mg/dL—translating to a 15% estimated decrease in cardiac event risk.
Unlike traditional risk factors or CCTA, Heartflow’s AI quantifies both calcified and soft plaque types, offering a precise, patient-specific risk profile. The Plaque Staging system classifies plaque burden into four risk categories validated by the FISH&CHIPS study, which found up to a fivefold increase in cardiovascular events for higher-risk groups.
“Heartflow Plaque Analysis empowers personalized care, enabling earlier intervention that can alter disease progression,” said Campbell Rogers, MD, Heartflow’s chief medical officer.
Experts view AI-based soft plaque quantification as a potential paradigm shift in coronary disease screening and prevention, supporting earlier detection and more tailored long-term management.
Follow MEDWIRE.AI for the latest in AI-driven cardiovascular diagnostics and innovations.
